Reuters: Health
Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment